Street Calls of the Week
Investing.com - Baird has reiterated an Outperform rating and $5.00 price target on Lineage Cell Therapeutics Inc. (NYSE:LCTX) following Roche’s R&D Day.
The research firm described its outlook as "incrementally positive" after Roche (OTC:RHHBY), Lineage’s partner, held its R&D day on Monday.
Baird noted that Roche included multiple slides on the OpRegen program during the presentation, signaling continued commitment to the collaboration.
The firm highlighted that Roche’s SVP of ophthalmology referred to OpRegen as a "personal favorite" during prepared remarks at the event.
These signals reinforce Baird’s belief that Roche remains committed to the program, particularly considering the context of an ongoing open-label Phase 2 study.
In other recent news, Lineage Cell Therapeutics reported its second quarter 2025 earnings, showcasing a significant revenue increase to $2.8 million, which exceeded analyst expectations. Despite the revenue boost, the company experienced a net loss of $0.13 per share, which was larger than anticipated. Additionally, the company announced a new initiative for a Type 1 diabetes treatment, leveraging its cell line manipulation expertise to develop an islet cell transplant program. H.C. Wainwright reaffirmed its Buy rating and set a price target of $9.00 for Lineage Cell Therapeutics following this announcement.
Furthermore, Lineage Cell Therapeutics entered into a research collaboration with William Demant Invest A/S to advance the development of ReSonance (ANP1), a cell therapy aimed at treating hearing loss. William Demant Invest will provide up to $12 million over three years to support preclinical development activities. This collaboration will focus on cell manufacturing, proof-of-concept studies, delivery development, and regulatory strategy. These developments highlight Lineage Cell Therapeutics’ ongoing efforts in expanding its therapeutic offerings and strategic partnerships.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.